4Mon·

$LLY (+0.37%)
$NVO (+0.77%)
$HIMS (+0.84%) | ELI LILLY LAUNCHES SINGLE-DOSE VIALS OF ZEPBOUND FOR WEIGHT LOSS IN U.S.


Eli Lilly has introduced single-dose vials of its weight-loss drug Zepbound in the U.S., offering 2.5 mg and 5 mg doses at $399 and $549 per month, respectively, via LillyDirect. 


This move aims to increase supply amid high demand and address insurance coverage gaps.


Despite the new availability, Zepbound remains on the FDA shortage list. The vials are priced 50% lower than other GLP-1 obesity drugs, targeting patients who can't get reimbursement.

7
4 Comments

profile image
Not so bad for $HIMS. Will still go massively uphill🔥🔥⛽️⛽️
1
profile image
@colonia_official Why do you think that
profile image
@Memo0606 Because the weight loss injections were never planned as a long-term mainstay at Hims. They only take it as a short-term opportunity. Their other products are nevertheless growing extremely strongly.
1
profile image
@colonia_official I'll buy $6367 and $FMG for now
unfortunately no more money for hims
but find them between 10-12$ exciting
Join the conversation